

| General Information | | | | | |
|------------------------------------|-------------------------|------------------------------------|--------------------|--------------------------|--------------------------------|
| EudraVigilance Local Report Number | EU-EC-10015000313 | | | | |
| Sender Type | Regulatory authority | | | | |
| Sender's Organisation | EEA Regulator | | | | |
| Type of Report | Spontaneous | | | | |
| Primary source country | European Economic Area | | | | |
| Reporter's qualification | Healthcare Professional | | | | |
| Case serious? | Yes | | | | |
| Patient | | | | | |
| Age Group | | Age Group (as per reporter) | | Sex | |
| More than 85 Years | | | | Female | |
| Reaction / Event | | | | | |
| MedDRA LLT | | Duration | Outcome | | Seriousness¹ |
| Bradycardia | | 1.0 Days | Recovered/Resolved | | hospital. |
| Drug Information | | | | | |
| Role² | Drug | Duration | Dose | Units in Interval | Action taken |
| S | VEKLURY - REMDESIVIR | 1.0 Days | 2.0 {DF} | | Drug withdrawn |
| Drug Information (cont.) | | | | | |
| Info³ | Drug | Indication | Pharm. Form | Route of Admin. | |
| | VEKLURY - REMDESIVIR | COVID-19 | | Intravenous use | |

1 Seriousness: **death**=results in death; **life threat.**=life threatening; **hospital.**=requires hospitalization/prolongation of hospitalization; **disability** =results in disability/incapacity; **congen.**=congenital anomaly/birth defect; **other**=other medically important information; **(blank)**=non-serious

2 Drug role: **S**=suspect; **C**=concomitant; **I**=interacting; **N**=not administered

3 Additional Information on Drug: **1**=Counterfeit; **2**= Overdose; **3**=Drug taken by the father; **4**=Drug taken beyond expiry date; **5**=Batch and lot tested and found within specifications; **6**=Batch and lot tested and found not within specifications; **7**=Medication error; **8**=Misuse; **9**=Abuse; **10** =Occupational exposure; **11**=Off label use; **(blank)**=no additional information